

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)



(10) International Publication Number
WO 2023/056388 A1

(51) International Patent Classification:

A61K 31/70 (2006.01) *A61K 47/51* (2017.01)
A61K 31/7088 (2006.01) *A61K 47/68* (2017.01)
A61K 31/713 (2006.01) *A61K 31/00* (2006.01)
A61K 47/50 (2017.01) *A61K 47/00* (2006.01)

(21) International Application Number:

PCT/US2022/077301

(22) International Filing Date:

29 September 2022 (29.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/250,135 29 September 2021 (29.09.2021) US
63/340,130 10 May 2022 (10.05.2022) US

(71) Applicants: **IONIS PHARMACEUTICALS, INC.**
[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).
BICYCLE TX LIMITED [GB/GB]; Building 900, Babraham
Research Campus, Cambridge GB CB22 3AT (GB).

(72) Inventors: **SETH, Punit, P.**; 6773 Mallee St., Carlsbad, CA 92011 (US). **OESTERGAARD, Michael**; 2855
Gazelle Court, Carlsbad, CA 92010 (US). **CARRER, Michele**; 2855 Gazelle Court, Carlsbad, CA 92010 (US).
TANOWITZ, Michael; 2855 Gazelle Court, Carlsbad, CA 92010 (US). **RIGBY, Michael**; Building 900, Babraham
Research Campus, Cambridge CB22 3AT (GB). **SKYNNER, Michael**; Building 900, Babraham Research Campus,
Cambridge CB22 3AT (GB). **STANWAY, Steven**; Building 900, Babraham Research Campus, Cambridge CB22
3AT (GB). **URBONAS, Liudvikas**; Building 900, Babraham Research Campus, Cambridge CB22 3AT (GB). **VAN
RIETSCHOTEN, Katerine**; Building 900, Babraham Research Campus, Cambridge CB22 3AT (GB).

(74) Agent: **SCARR, Rebecca B.** et al.; McNeill Baur PLLC,
125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF

(57) Abstract: Provided herein are oligomeric compounds comprising a bicycle ligand and a modified oligonucleotide. This compound may comprise a bicycle ligand as the cell-targeting moiety, and may also comprise a conjugate linker to connect the bicycle ligand and modified oligonucleotide. This compound may be used in conjunction with a pharmaceutically acceptable salt.

WO 2023/056388 A1